Robert Palmisano Buys Shares of RxSight, Inc.
Robert Palmisano purchased 37,037 shares of RxSight, Inc. on June 17, 2026.
Key Points
- Robert Palmisano acquired 37,037 shares of RxSight, Inc. on June 17, 2026.
- RxSight's stock is trading near $4.73, with a market cap of $195.8 million and a 52-week range of $4.48 to $14.25.
- Analysts from Needham and Wells Fargo maintain varied ratings, with price targets ranging from $9 to $13.
On June 17, 2026, Robert Palmisano bought 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). This insider transaction was not planned under a Rule 10b5-1 trading plan.
Other Institutional Activity in RxSight, Inc.
Among institutional investors, BlackRock, Inc. increased its holdings by 482,086 shares to a total of 3,187,092 shares, valued at approximately $19.6 million. Meanwhile, Millennium Management LLC and Artisan Partners Limited Partnership slightly reduced their positions by 69,579 and 98,580 shares, respectively. Nomura Holdings Inc. maintained its stake with 2,000,060 shares worth about $12.3 million, while No Street GP LP added 25,000 shares, bringing its total to 2,000,000 shares.
RxSight, Inc. Stock Snapshot
Shares of RxSight, Inc. traded around $4.73. The company has a market capitalization of about $195.8 million. With a forward P/E ratio of -8.45, the stock's beta is 1.134. The 52-week trading range is between $4.48 and $14.25, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. The company's current ratio is 10.2, and its quick ratio is 8.779, while the debt-to-equity ratio stands at 4.05.
Recent Earnings
RxSight reported revenue of $127.5 million, though it experienced a revenue decline of 18.5%. The company's net margin is -36.6%, and its return on equity is -17.1%. Earnings per share (EPS) is -$1.13. The next earnings report is expected on August 6, 2026.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a 'hold' rating with a price target of $9. Needham, on the same day, kept a 'buy' rating with a target of $11. The consensus among analysts suggests a mean target price of $8.79 across seven opinions.
About RxSight, Inc.
RxSight, Inc. is a healthcare company based in Aliso Viejo, California. It specializes in medical devices, particularly light adjustable intraocular lenses (LAL) for cataract surgery. The company's RxSight system allows doctors to customize visual acuity post-surgery. Dr. Ronald M. Kurtz M.D. leads the company, which employs around 461 people.
Bottom Line
Insider buying by Robert Palmisano at RxSight, Inc. highlights ongoing interest in the company's potential despite recent financial challenges. Investors often track such insider activities for insights into management's confidence in the business. As a reminder, these activities reflect past transactions and may not indicate current or future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.